Free Trial

Tiziana Life Sciences (TLSA) Competitors

Tiziana Life Sciences logo
$1.48 +0.01 (+0.68%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.48 +0.00 (+0.07%)
As of 07/11/2025 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TLSA vs. TRVI, ANAB, IMTX, DAWN, MRVI, AUTL, STOK, URGN, PHAT, and RLAY

Should you be buying Tiziana Life Sciences stock or one of its competitors? The main competitors of Tiziana Life Sciences include Trevi Therapeutics (TRVI), AnaptysBio (ANAB), Immatics (IMTX), Day One Biopharmaceuticals (DAWN), Maravai LifeSciences (MRVI), Autolus Therapeutics (AUTL), Stoke Therapeutics (STOK), Urogen Pharma (URGN), Phathom Pharmaceuticals (PHAT), and Relay Therapeutics (RLAY). These companies are all part of the "pharmaceutical products" industry.

Tiziana Life Sciences vs. Its Competitors

Trevi Therapeutics (NASDAQ:TRVI) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Trevi Therapeutics presently has a consensus target price of $20.88, suggesting a potential upside of 218.70%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Trevi Therapeutics is more favorable than Tiziana Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trevi Therapeutics
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
3 Strong Buy rating(s)
3.30
Tiziana Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

95.8% of Trevi Therapeutics shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Trevi Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of -0.05, meaning that its stock price is 105% less volatile than the S&P 500.

In the previous week, Tiziana Life Sciences had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 3 mentions for Tiziana Life Sciences and 2 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 0.95 beat Tiziana Life Sciences' score of 0.63 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Trevi Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tiziana Life Sciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Tiziana Life Sciences' return on equity of 0.00% beat Trevi Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Trevi TherapeuticsN/A -58.41% -52.52%
Tiziana Life Sciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevi TherapeuticsN/AN/A-$47.91M-$0.45-14.56
Tiziana Life SciencesN/AN/A-$11.86MN/AN/A

Summary

Trevi Therapeutics beats Tiziana Life Sciences on 7 of the 12 factors compared between the two stocks.

Get Tiziana Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TLSA vs. The Competition

MetricTiziana Life SciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$171.77M$2.97B$5.62B$9.10B
Dividend YieldN/A2.39%5.24%4.00%
P/E RatioN/A20.7128.1020.27
Price / SalesN/A292.05429.7099.23
Price / CashN/A42.8637.4658.16
Price / Book37.007.638.045.49
Net Income-$11.86M-$55.05M$3.18B$250.45M
7 Day Performance-3.90%8.43%3.61%4.77%
1 Month Performance4.23%5.42%4.04%7.67%
1 Year Performance83.17%2.03%29.99%16.38%

Tiziana Life Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TLSA
Tiziana Life Sciences
1.3561 of 5 stars
$1.48
+0.7%
N/A+80.5%$171.77MN/A0.008News Coverage
TRVI
Trevi Therapeutics
3.9142 of 5 stars
$5.95
flat
$20.88
+250.8%
+133.1%$697.89MN/A-13.2220
ANAB
AnaptysBio
1.7492 of 5 stars
$23.45
-1.3%
$42.38
+80.7%
-13.6%$697.79M$91.28M-4.84100Positive News
IMTX
Immatics
3.1189 of 5 stars
$5.53
-3.2%
$14.67
+165.2%
-51.2%$694.05M$168.65M-32.53260
DAWN
Day One Biopharmaceuticals
2.5157 of 5 stars
$6.63
-2.5%
$30.57
+361.1%
-55.0%$689.27M$131.16M-9.3460News Coverage
MRVI
Maravai LifeSciences
3.6185 of 5 stars
$2.60
-2.6%
$6.64
+155.3%
-68.3%$679.94M$259.18M-2.28610Positive News
Options Volume
AUTL
Autolus Therapeutics
2.877 of 5 stars
$2.26
-4.6%
$9.32
+312.4%
-40.5%$630.76M$10.12M-2.57330
STOK
Stoke Therapeutics
4.1423 of 5 stars
$11.69
+1.8%
$23.20
+98.5%
-15.5%$626.77M$36.56M14.80100Trending News
URGN
Urogen Pharma
4.5328 of 5 stars
$13.49
-0.7%
$32.86
+143.6%
-15.7%$626.14M$90.40M-4.24200Analyst Forecast
PHAT
Phathom Pharmaceuticals
4.2116 of 5 stars
$8.66
-2.9%
$17.50
+102.1%
-18.9%$622.74M$55.25M-1.65110
RLAY
Relay Therapeutics
2.1718 of 5 stars
$3.55
-2.2%
$17.67
+397.7%
-53.6%$622.34M$10.01M-1.59330News Coverage
Insider Trade

Related Companies and Tools


This page (NASDAQ:TLSA) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners